Document:

EX-10.16.2

 Exhibit 10.16.2 

FIRST AMENDMENT TO 
 JOINT DEVELOPMENT AGREEMENT DATED NOVEMBER 26, 2008 
 This FIRST
AMENDMENT to the Joint Development Agreement dated November 26, 2008 (this “First Amendment”) is effective as of the date of last signature (“Amendment Effective Date”) and is made and entered into by and
between Impax Laboratories, Inc., a Delaware corporation, with its principal place of business at 30831 Huntwood Avenue, Hayward, California 94544 (“Impax”) and Medicis Pharmaceutical Corporation, a corporation organized
under the laws of the State of Delaware, with its principal place of business at 7720 North Dobson Road, Scottsdale, Arizona, 85256 (“Medicis”). 
 RECITALS: 
 WHEREAS, Medicis and Impax are parties to the Joint Development
Agreement dated November 26, 2008 (the “Agreement”), and wish to further amend the Agreement as herein provided. 
 NOW, THEREFORE, in consideration of the foregoing recitals, covenants, and representations set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, Impax and Medicis agree as follows: 
 1. Terms used herein without definition are as defined in the Agreement. 

2. Exhibit A of the Agreement. Exhibit A of the Agreement is hereby deleted in its entirety and replaced with the new Exhibit A
attached to this First Amendment as Attachment No. 1. 
 3. Section 2.3.1. Section 2.3.1 of the Agreement is amended as
follows (for convenience additions are indicated by bold underlined text and deletions are indicated by hold strikethrough text): 
 2.3.1 Composition, Duties, and Authority of the Steering Committee. The Steering Committee shall foster the collaborative relationship between the parties and shall in particular monitor the
progress of the Development Program and Impax’s progress with respect to the ANDA Products. The Steering Committee shall he comprised of two (2) named representatives of Impax and two (2) named representatives of Medicis. Each party
shall appoint its respective representatives to the Steering Committee from time to time, and may substitute one or more of its representatives, in its sole discretion, effective upon notice to the other party of such change but shall use
commercially reasonable efforts to maintain stability of Steering Committee representation. The Steering Committee shall not have the power to amend the-terms-of this Agreement but shall have the power to change the
Development Plan upon the written agreement of at least one (1) representative of the Steering Committee from each party. The Steering Committee also may amend the Target Product Profile upon written agreement of at least
one (1) representative of the Steering Committee from each party. The Steering Committee shall not have any other power to amend the terms of this Agreement. 
 4. Binding Effect. Except as modified in this First Amendment, the Agreement shall remain unchanged. The parties represent and warrant that, as of the Amendment Effective Date, no other agreements,
written or oral, exist between the Parties with respect to the subject matter covered herein except for the Agreement and the First Amendment. The parties acknowledge and agree that in the event of a conflict between the terms amended pursuant to
this First Amendment and the other terms of the Agreement, the terms of this First Amendment shall govern. 
 5. Counterparts. This First
Amendment may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall be deemed one and the same instrument. 
 6. Authority. Each party represents and warrants to the other party that this First Amendment is being executed by the authorized representatives of each party. 

 IN WITNESS WHEREOF, the parties hereto have caused this First Amendment to be executed by
their duly authorized representatives as of the Amendment Effective Date. 
  

									
	IMPAX LABORATORIES. INC.	 		 	MEDICIS PHARMACEUTICAL CORPORATION
					
	By: 	 	/s/ Arthur A. Koch, Jr.	 		 	By:	 	/s/ Richard D. Peterson
		 	 Arthur A. Koch, Jr.
 SVP –
CFO
	 		 		 	 Richard D. Peterson

Executive Vice President, Treasurer and CFO

					
	Date:	 	 1/5/11
	 		 	Date:	 	 1/26/2011EX-10.17.2

 Exhibit 10.17.2 
 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 
 EXECUTION 
 FIRST AMENDMENT OF 
 THE LICENSE, DEVELOPMENT AND COMMERCIALIZATION
AGREEMENT 
 This FIRST AMENDMENT OF THE
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (THIS “First Amendment”) is made and effective as of December 23, 2011 (the
“First Amendment Effective Date”) by and between IMPAX LABORATORIES, INC., a Delaware corporation with its principal place of business at 30831 Huntwood Avenue, Hayward, CA 94544
(“Impax”), and GLAXO GROUP LIMITED, a company organized and existing under the laws of England and having an office and place of business at Glaxo Wellcome House, Berkeley Avenue,
Greenford, Middlesex, UB6 ONN, United Kingdom (“GSK”). 
 WHEREAS, Impax and GSK are parties to
certain License, Development and Commercialization Agreement, entered into as of December 15, 2010 (the “License Agreement”); 
 WHEREAS, Impax and GSK now desire to amend certain terms and conditions of the License Agreement as set forth below. 
 NOW THEREFORE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this First Amendment, the Parties agree as follows: 

 

	1.	Section 4.5(a) is hereby deleted and replaced in its entirety with the following: 

“(a) [***].” 
  

	2.	Section 4.5(b) is hereby deleted and replaced in its entirety with the following: 

“(b) [***];” 

  
 1 

	3.	Section 4.5(d) is hereby deleted and replaced in its entirety with the following: 

“(d) [***]; and” 
  

	4.	Section 7.3(a) is hereby deleted and replaced in its entirety with the following: 

“(a) [***]. GSK shall notify Impax within [***]. After the receipt of such notice, Impax shall submit to GSK
an invoice of [***] Dollars ($[***]) and GSK shall pay to Impax the amount invoiced within ten (10) days after the receipt of such invoice.” 
 5. This First Amendment amends the terms of the License Agreement as expressly provided above, and the License Agreement, as so amended and including all of its other terms and provisions that are
not amended, remains in full force and effect and sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect
to the subject matter of the License Agreement and supersedes, as of the First Amendment Effective Date, all prior and contemporaneous agreements and understandings between the Parties with respect to the subject matter of the License Agreement.
There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as set forth in the License Agreement (as amended by this First Amendment). 

6. Capitalized terms used but not defined herein shall have the meanings set forth in the License Agreement. For clarity, the term
“Agreement” in the License Agreement means the License, Development and Commercialization Agreement as amended. 
 7. The
validity, performance, construction, and effect of this First Amendment shall be governed by and construed under the laws of the State of Delaware, without giving effect to any choice of law principles that would require the application of the laws
of a different state. This First Amendment may be executed in one (1) or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument. 

[Signature page follows] 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
has been requested with respect to the omitted portions. 

  
 2 

 IN WITNESS WHEREOF, the
Parties have executed this First Amendment in duplicate originals by their proper representatives as of the First Amendment Effective Date. 
  

									
	GLAXO GROUP LIMITED	 		 	IMPAX LABORATORIES, INC.
					
	By:	 	/s/ Paul Williamson	 		 	By:	 	/s/ Michael Nestor
					
	Name:	 	Paul Williamson	 		 	Name:	 	Michael Nestor
	Title:	 	Authorized Signatory For and on behalf of Edinburgh Pharmaceutical Industries Limited Corporate Director	 		 	Title:	 	President, Impax Pharmaceuticals

 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 3The Amended Schedule to the Forms of Indemnification Agreement

 Exhibit 10.16.1 

Amended Schedule to the Forms of 
 Indemnification Agreement 
 Sunoco, Inc. has entered into Indemnification Agreements with the
directors, executive officers, trustees, fiduciaries, employees or agents named below: 
  

					
	 Employee
	  	 	  	 Date of Agreement

		  		  	
	Anne-Marie Ainsworth	  		  	November 2, 2009
	Elizabeth G. Bilotta	  		  	June 30, 2010
	Vincent J. Brigandi, Jr.	  		  	June 30, 2010
	Michael J. Colavita	  		  	March 1, 2012
	Robert N. Deitz	  		  	December 2, 2009
	Lynn L. Elsenhans	  		  	August 8, 2008
	Stacy L. Fox	  		  	March 1, 2010
	Marilyn Heffley	  		  	December 2, 2009
	Joseph P. Krott	  		  	March 4, 2004
	Brian P. MacDonald	  		  	August 10, 2009
	Marie A. Natoli	  		  	March 3, 2006
	Robert W. Owens	  		  	March 4, 2004
	John D. Pickering	  		  	May 5, 2011
	Thomas J. Scargle	  		  	July 2, 2009
	Charmian Uy	  		  	December 3, 2009
	Dennis Zeleny	  		  	January 20, 2009
			
	  
	  		  	
			
	Robert M. Aiken, Jr.*	  		  	February 1, 1996
	Robert H. Campbell*	  		  	February 1, 1996
	John F. Carroll*	  		  	March 4, 2004
	Terence P. Delaney*	  		  	March 4, 2004
	Michael H. R. Dingus*	  		  	March 4, 2004
	John G. Drosdick*	  		  	March 4, 2004
	Bruce G. Fischer*	  		  	March 4, 2004
	Jack L. Foltz*	  		  	February 1, 1996
	David E. Knoll*	  		  	February 1, 1996
	Deborah M. Fretz*	  		  	September 6, 2001
	Peter J. Gvazdauskas *	  		  	February 4, 2009
	Frederick A. Henderson*	  		  	September 1, 2010
	Michael J. Hennigan*	  		  	February 2, 2006
	Thomas W. Hofmann*	  		  	March 4, 2004
	Vincent J. Kelley*	  		  	February 2, 2006
	Michael S. Kuritzkes*	  		  	March 4, 2004
	Michael J. McGoldrick *	  		  	March 4, 2004
	Joel H. Maness*	  		  	March 4, 2004
	Christopher J. Minnich*	  		  	June 1, 2009
	Ann C. Mulé*	  		  	March 4, 2004
	Paul A. Mulholland*	  		  	March 4, 2004
	Rolf D. Naku*	  		  	March 4, 2004
	Alan J. Rothman*	  		  	March 4, 2004
	Bruce D. Rubin*	  		  	October 15, 2008
	Malcolm I. Ruddock, Jr.*	  		  	February 1, 1996
	David C. Shanks*	  		  	February 17, 1997
	Sheldon L. Thompson *	  		  	February 1, 1996
	Michael J. Thomson*	  		  	May 30, 2008
	Ross S. Tippin, Jr.*	  		  	March 4, 2004
	Charles K. Valutas*	  		  	March 4, 2004

					
	 Director
	  	 	  	 Date of Agreement

		  		  	
	Chris C. Casciato	  		  	July 1, 2010
	Irene Chang-Britt	  		  	November 30, 2011
	William H. Easter, III	  		  	November 30, 2011
	Gary W. Edwards	  		  	May 1, 2008
	Ursula O. Fairbairn	  		  	March 4, 2004
	John P. Jones, III	  		  	September 8, 2006
	James G. Kaiser	  		  	March 4, 2004
	John K. Wulff	  		  	March 8, 2004
			
	  
	  		  	
			
	Raymond E. Cartledge**	  		  	September 6, 2001
	Robert E. Cawthorn**	  		  	February 1, 1996
	Robert J. Darnall**	  		  	March 4, 2004
	John G. Drosdick**	  		  	March 4, 2004
	Mary J. Evans**	  		  	September 6, 2001
	Thomas P. Gerrity**	  		  	March 4, 2004
	Rosemarie B. Greco**	  		  	March 4, 2004
	Robert D. Kennedy**	  		  	September 6, 2001
	Richard H. Lenny**	  		  	February 8, 2002
	Norman S. Matthews**	  		  	September 6, 2001
	R. Anderson Pew**	  		  	March 4, 2004
	William B. Pounds**	  		  	February 1, 1996
	G. Jackson Ratcliffe**	  		  	March 4, 2004
	John W. Rowe**	  		  	March 4, 2004

  

	*	In a different position or no longer with the Company 

	**	No longer serving on the Board 

  
 Page 2 of 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}]]